A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
Under a Creative Commons license
open access
Keywords
Duchenne muscular dystrophy
Drisapersen
Dystrophin
Antisense oligonucleotide
Exon skipping
six-minute walking distance
Cited by (0)
- 1
Member of the DEMAND III study team 2.
© 2017 The Authors. Published by Elsevier B.V.